Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Public ClinicalTrials.gov record NCT05041309. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene autoleucel, INT2104, KITE-512, ACLX-001, and ACLX002 in participants of Kite-sponsored interventional studies. The primary objectives of this study are to: * Evaluate the incidence and severity of related SAEs, late-onset targeted AEs/SAEs suspected to be possibly related to gene-modified cell therapy, including neurologic disorders, new autoimmune disorders (which are distinct from the study-treated disease), hematologic disorders, serious infections, as well as any new malignancies (regardless of causality) * Evaluate the growth, development, and sexual maturity of pediatric and adolescent participants treated with gene-modified cell therapy.
Study identification
- NCT ID
- NCT05041309
- Recruitment status
- Enrolling by invitation
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,500 participants
Conditions and interventions
Interventions
- Axicabtagene Ciloleucel Biological
- Brexucabtagene Autoleucel Biological
- Anitocabtagene autleucel Biological
- KITE-753 Biological
- KITE-197 Biological
- KITE-363 Biological
- INT2104 Biological
- KITE-512 Biological
- SPRX001 Biological
- SPRX002 Biological
- ARC-T Cells Biological
Biological
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2021 (Actual)
- Primary completion
- Dec 2040 (Estimated)
- Completion
- Dec 2040 (Estimated)
- Last update posted
- Sep 21, 2026
2021 – 2040
United States locations
- U.S. sites
- 49
- U.S. states
- 24
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| City of Hope | Duarte | California | 91010 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Children's Hospital Los Angeles | Los Angeles | California | 90027 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Children's Hospital of Orange County | Orange | California | 92868 | — |
| Stanford University | Palo Alto | California | 94305 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of California, San Francisco Medical Center | San Francisco | California | 94143 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Sylvester Comprehensive Cancer Centre | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Ann& Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | — |
| University of Chicago Medical Center Clinical Laboratories | Chicago | Illinois | 60637 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| The University of Kansas Cancer Center Westwood | Westwood | Kansas | 66205 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Center Institute | Detroit | Michigan | 48201 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| University of Nebraska | Omaha | Nebraska | 68198 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Ichann School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Mayo Clinic | Rochester | New York | 55905 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| DUHS-Duke Blood Cancer Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43220 | — |
| The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29615 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| St. David's Medical Center | Austin | Texas | 78704 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Sarah Cannon-Methodist Healthcare System - San Antonio | San Antonio | Texas | 78229 | — |
| Intermountain LDS Hospita;/Blood and Marrow Transplant/ Acute Leukemia Program | Salt Lake City | Utah | 84143 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05041309, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05041309 live on ClinicalTrials.gov.